Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

XL-protein GmbH (XLp)

XL-protein GmbH, a privately held German biopharmaceutical company, has its headquarters in Freising-Weihenstephan. XL-protein uses its proprietary PASylation® technology to develop next-generation biologics with extended plasma half-life and prolonged action. XL-protein was founded in 2009 as a spin-off from the Technical University of Munich (TUM). With its strong and proprietary technology position, Xlprotein focuses on both the preclinical and clinical development of PASylated protein-based and peptide-based drugs in commercially attractive disease areas. XL-protein licenses its PASylation® technology to other users and operates partnerships with a number of international pharmaceutical and biotechnology companies. *


Period Start 2009-01-01 splitoff
  Predecessor Technical University Munich (TU München, TUM)
Products Industry BIOTECH
  Industry 2 PASylation® technology
Persons Person Skerra, Arne (XL-protein GmbH 201104 Managing Director)
  Person 2 Schalper, Claus (XL-protein 201410 Managing Director (CEO) before Pieris 201101 CFO)
Region Region Freising
  Country Germany
  Street 30 Lise-Meitner-Str.
  City 85354 Freising
  Tel +49-8161-53730-90
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: 
Record changed: 2018-10-31


Picture [iito] Plain Stupid Simple 650x80px

More documents for XL-protein GmbH (XLp)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top